Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
becotatug vedotin + ivonescimab
- Development stage
- Unknown
- Lead developer
- Lepu Biopharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy pairs becotatug vedotin (MK-2870/SKB264), a TROP2-directed antibody-drug conjugate (ADC), with ivonescimab (AK112), a bispecific antibody targeting PD-1 and VEGF. Becotatug vedotin utilizes a humanized monoclonal antibody to deliver a potent topoisomerase I inhibitor payload directly to TROP2-expressing cancer cells. Ivonescimab concurrently inhibits the PD-1/PD-L1 immune checkpoint and the VEGF-mediated angiogenic pathway, potentially creating a synergistic effect by enhancing T-cell infiltration and normalizing tumor vasculature. This specific combination is being evaluated by West China Hospital in a Phase II clinical trial as a neoadjuvant treatment for patients with resectable locally advanced head and neck squamous cell carcinoma (LAHNSCC) to improve pathological complete response rates and surgical outcomes.
- Other names
- Becotatug vedotin plus ivonescimab
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on becotatug vedotin + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on becotatug vedotin + ivonescimab.